Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026
Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Fineline Cube Jan 10, 2026
Company Drug

Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer

Fineline Cube Dec 10, 2024

Immunofoco, a leading developer in tumor immunotherapy based in Suzhou, has announced that it has...

Company Drug

InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment

Fineline Cube Dec 10, 2024

Beijing-based gene therapy specialist InnoVec Biotherapeutics Inc. has announced receiving Investigational New Drug (IND) approval...

Company Deals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Fineline Cube Dec 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...

Company Drug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Fineline Cube Dec 10, 2024

Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Fineline Cube Dec 10, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...

Company Deals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

Fineline Cube Dec 10, 2024

Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...

Company Drug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Fineline Cube Dec 10, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...

Company Drug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...

Company Drug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Fineline Cube Dec 10, 2024

US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...

Company Drug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

Fineline Cube Dec 10, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...

Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Fineline Cube Dec 10, 2024

The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...

Company Deals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Fineline Cube Dec 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...

Company Drug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...

Company Drug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Fineline Cube Dec 10, 2024

China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Fineline Cube Dec 10, 2024

The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...

Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

Fineline Cube Dec 10, 2024

The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...

Company Drug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

Fineline Cube Dec 10, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...

Company Drug

GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data

Fineline Cube Dec 10, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that the US Food and Drug Administration...

Company Deals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Fineline Cube Dec 10, 2024

China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...

Posts pagination

1 … 189 190 191 … 606

Recent updates

  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
  • MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
  • Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
  • Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.